These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25901160)

  • 1. Comparing the Effect of Silybin and Silybin Advanced™ on Viability and HER2 Expression on the Human Breast Cancer SKBR3 Cell Line by no Serum Starvation.
    Mahmoodi N; Motamed N; Paylakhi SH; O Mahmoodi N
    Iran J Pharm Res; 2015; 14(2):521-30. PubMed ID: 25901160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Comparison of The Effects of Silybin and Silybin-Phosphatidylcholine on Viability and ESR Expression in Human Breast Cancer T47D Cell Line.
    Mahmoodi N; Motamed N; Paylakhi SH
    Cell J; 2014; 16(3):299-308. PubMed ID: 24611152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Geldanamycin inhibits proliferation and motility of human HER2/neu-overexpressing breast cancer cell line SKBr3].
    Wang K; Ma QY; Ren Y; He JJ; Chen WK
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1480-4. PubMed ID: 17959518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.
    Lazzeroni M; Guerrieri-Gonzaga A; Gandini S; Johansson H; Serrano D; Cazzaniga M; Aristarco V; Puccio A; Mora S; Caldarella P; Pagani G; Pruneri G; Riva A; Petrangolini G; Morazzoni P; DeCensi A; Bonanni B
    Cancer Prev Res (Phila); 2016 Jan; 9(1):89-95. PubMed ID: 26526990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
    Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
    BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.
    Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
    Int J Mol Med; 2008 Oct; 22(4):433-9. PubMed ID: 18813848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway.
    Bowers LW; Wiese M; Brenner AJ; Rossi EL; Tekmal RR; Hursting SD; deGraffenried LA
    PLoS One; 2015; 10(12):e0145452. PubMed ID: 26709918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells.
    Zappavigna S; Vanacore D; Lama S; Potenza N; Russo A; Ferranti P; Dallio M; Federico A; Loguercio C; Sperlongano P; Caraglia M; Stiuso P
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31058823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of single versus combined use of trastuzumab and cantide on breast cancer cells SKBR3 over-expressing HER2].
    Zhang F; Yang JL; You JH; Feng F; Ren L; Xie WX; Li ZJ
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(20):1384-7. PubMed ID: 22883194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos).
    Kidd P; Head K
    Altern Med Rev; 2005 Sep; 10(3):193-203. PubMed ID: 16164374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
    Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
    Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
    Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
    Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of a silybin-phosphatidylcholine complex in dogs.
    Filburn CR; Kettenacker R; Griffin DW
    J Vet Pharmacol Ther; 2007 Apr; 30(2):132-8. PubMed ID: 17348898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silybin Showed Higher Cytotoxic, Antiproliferative, and Anti-Inflammatory Activities in the CaCo Cancer Cell Line while Retaining Viability and Proliferation in Normal Intestinal IPEC-1 Cells.
    Faixová D; Ratvaj M; Maruščáková IC; Hrčková G; Karaffová V; Faixová Z; Mudroňová D
    Life (Basel); 2023 Feb; 13(2):. PubMed ID: 36836848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells.
    Vecchione G; Grasselli E; Voci A; Baldini F; Grattagliano I; Wang DQ; Portincasa P; Vergani L
    World J Gastroenterol; 2016 Jul; 22(26):6016-26. PubMed ID: 27468193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
    Papadakis E; Robson N; Yeomans A; Bailey S; Laversin S; Beers S; Sayan AE; Ashton-Key M; Schwaiger S; Stuppner H; Troppmair J; Packham G; Cutress R
    Oncotarget; 2016 Apr; 7(14):18851-64. PubMed ID: 26958811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.